0008-0100 : Besponsa .25 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution


NDC: 0008-0100
Labeler: Wyeth Pharmaceuticals Inc., a Subsidiary of Pfizer Inc.
Product Type: Human Prescription Drug
Drug Name:  Besponsa
Dosage Form: Intravenous Injection, Powder, Lyophilized, for Solution
Application #: BLA761040
Rev. Date: 


NDC Package Codes:

  • 0008-0100-01: 1 VIAL, SINGLE‑DOSE IN 1 CARTON (0008‑0100‑01) > 4 ML IN 1 VIAL, SINGLE‑DOSE

Active Ingredients:

  • Inotuzumab Ozogamicin

Dosage Strength:

  • .25 mg/mL

Pharmaceutical Classes:

  • CD22-directed Antibody Interactions [MoA]
  • CD22-directed Immunoconjugate [EPC]
  • Decreased DNA Integrity [PE]
  • Immunoconjugates [CS]
  • Increased Cellular Death [PE]

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 0008-0100 QR Code

< Prev: 0008-0045Next: 0008-0407 >




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.